Taxotere (chemotherapy for prostate cancer) is administered intravenously usually in an cancer center or a hospital setting. Often the areas which are designated for chemo administration are referred to as infusion centers. Taxotere is administered with either on a higher dosage schedule of once every three weeks (q3wk) or a lower dosage schedule of once [...]
The current standard of care in the treatment of prostate cancer is to use chemotherapy (Taxotere) only in late stage hormone refractory prostate cancer. Most other cancers use chemotherapy agents at a much earlier stage then used for prostate cancer. Prostate cancer cells divide at a rate that is not much faster than normal cell [...]
April 14 in the Journal of Clinical Oncology reported that Eric M. Horwitz, M.D., from Fox Chase Cancer Center in Philadelphia, and colleagues treated 1,554 prostate cancer patients with goserelin and flutamide (ADT) before and during radiation therapy. The men were then randomly assigned to receive no further ADT or 24 additional months of ADT. [...]
When I provided testimony at the FDA in support of the application for approval of the vaccine Provenge®, I had the opportunity of meeting some of the representatives of the biotech company Antigenics (AGEN). Since I am also a renal cancer survivor they initially approached me asking if I would be willing to meet them [...]
I want to apologize because I have not posted anything in the last few days. I thank the few people who sent an e-mail expressing concern. On Friday evening I flew to San Diego with my wife to participate in the American Association of Cancer Researchers (AACR) Scientist-Survivor program. It is a really fantastic program [...]